JAGUAR HEALTH, INC. Cash and Restricted Cash
JAGUAR HEALTH, INC. (JAGX) had Cash and Restricted Cash of $6.59 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-19
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.59M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.06M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.83M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.53M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $6.59M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $10.06M 10-Q · filed 2026-05-20 | |
| 2025-12-31 | $7.83M 10-Q · filed 2026-08-19 | |
| 2025-09-30 | $3.53M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $2.21M 10-Q · filed 2026-08-19 | |
| 2025-03-31 | $5.69M 10-Q · filed 2026-05-20 | $5.69M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $8.00M 10-Q · filed 2026-08-19 | |
| 2024-09-30 | $13.27M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $16.05M 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $11.67M 10-Q · filed 2025-05-15 | |
| 2023-12-31 | $6.47M 10-K · filed 2026-04-07 | |
| 2023-09-30 | $3.23M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $8.63M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $14.37M 10-Q · filed 2024-05-14 | |
| 2022-12-31 | $5.47M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $10.56M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $9.01M 10-Q · filed 2023-08-14 | |
| 2022-03-31 | $17.46M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $17.05M 10-K · filed 2024-04-01 | |
| 2021-09-30 | $12.38M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $31.91M 10-Q · filed 2022-08-22 | |
| 2021-03-31 | $32.25M 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $8.09M 10-K · filed 2023-03-24 | |
| 2020-09-30 | $1.35M 10-Q · filed 2021-11-17 | |
| 2020-06-30 | $3.02M 10-Q · filed 2021-08-13 | |
| 2020-03-31 | $1.60M 10-Q · filed 2021-05-17 | |
| 2019-12-31 | $3.88M 10-K · filed 2022-03-11 | $3.88M 10-K · filed 2020-04-03 |
| 2019-09-30 | $2.07M 10-Q · filed 2020-11-16 | $2.07M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $1.61M 10-Q · filed 2020-08-13 | $1.61M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $2.57M 10-Q · filed 2020-05-15 | $2.57M 10-Q · filed 2019-05-21 |
| 2018-12-31 | $2.57M 10-K · filed 2021-03-31 | $2.57M 10-K · filed 2019-04-10 |
| 2018-09-30 | $726.13K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $2.41M 10-Q · filed 2019-08-14 | |
| 2018-03-31 | $7.81M 10-Q · filed 2019-05-21 | |
| 2017-12-31 | $759.87K 10-K · filed 2020-04-03 | $759.87K 10-Q · filed 2018-08-13 |
| 2017-09-30 | $220.59K 10-Q · filed 2018-11-19 | |
| 2017-06-30 | $2.76M 10-Q · filed 2018-08-13 | |
| 2016-12-31 | $1.46M 10-K · filed 2019-04-10 | $1.46M 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |